Autoimmune disease

This early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…

This study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…

This study compares a new insulin pump system, Omnipod 6, to the current Omnipod 5 in 200 people with type 1 or type 2 diabetes who have poor blood sugar control. Participants will use both pumps for a set time to see which one helps keep blood sugar in a healthy range more effec…

This study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…

This Phase 1 trial tests surovatamig, a bispecific T-cell engager, in 48 adults with rheumatoid arthritis or systemic lupus erythematosus. The study gives the drug as injections in increasing doses to check safety, side effects, and how the body processes it. It is too early to k…

This study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.

This study investigates whether a single infusion of a patient's own genetically modified immune cells (CD19 CAR-T cells) can safely control moderate-to-severe pemphigus vulgaris that hasn't responded to standard treatments. The therapy targets and depletes B cells, which are tho…

This study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…

This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…

This study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …

This study looks at how well a particular revision ACL surgery works over the long term. The technique uses a donor Achilles tendon and an extra stitch on the outside of the knee. Researchers will check knee function, stability, and arthritis development in 59 people who had this…

This study tests a new biologic drug called ianalumab combined with a standard platelet-boosting drug (TPO-RA) in people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial includes 164 adults who have tried at l…

This study looks at how well the Omnipod 5 Automated Insulin Delivery System works in real-world settings for people with type 1 diabetes. About 152 participants aged 2 and older will use the system for the first time. The goal is to see if it helps keep blood sugar levels in a h…

This phase 2 trial tests whether the experimental drug E6742 can reduce lupus disease activity better than a placebo. About 256 adults with lupus will take either E6742 or a placebo pill for 24 weeks. The main goal is to see if more people on E6742 achieve a meaningful reduction …

This study tests a new drug, CNP-103, in people aged 12 to 35 who were diagnosed with stage 3 type 1 diabetes within the last 6 months. The goal is to see if the drug is safe and can help control the disease. Participants will receive either the drug or a placebo, and researchers…

This study tests whether teplizumab, a drug already approved in the US, can safely delay the start of full-blown type 1 diabetes in Japanese people aged 8 to 34 who are at high risk (Stage 2). Participants will receive a 14-day IV treatment and be monitored for side effects and h…

This phase 2 trial tests whether NLY01, a drug similar to those used for diabetes, can slow brain and retinal shrinkage in people with multiple sclerosis. About 120 adults with stable MS will receive either NLY01 or a placebo for 96 weeks. The main goal is to see if the drug redu…

This study follows adults who have received a Tipmed shoulder replacement to see how well the implant works and if any problems arise over the first year. Participants have conditions like severe arthritis, rotator cuff damage, or a broken shoulder bone. Researchers track shoulde…

This phase 3 study tests whether the oral drug rilzabrutinib can prevent disease flares in adults with active IgG4-related disease, a rare condition causing swelling and organ damage. About 124 participants will receive either rilzabrutinib or a placebo for 52 weeks, alongside st…

This study will follow 2,200 children and adults with type 1 diabetes who are using the Omnipod 5 system, a tubeless insulin pump that automatically adjusts insulin based on continuous glucose monitor readings. Over 12 months, researchers will track how often severe low or high b…

This study tests whether a supplement called nicotinamide riboside (NR) can reduce inflammation and improve immune cell function in women with mild-to-moderate lupus. About 78 participants will receive either NR or a placebo for 12 weeks. Researchers will measure changes in immun…

This study tests an experimental pill called NMD670 in 84 adults with myasthenia gravis, a condition that causes muscle weakness. Participants take the pill or a placebo twice daily for 21 days. Researchers will measure changes in muscle strength and daily activities to see if th…

This study looks at whether taking coenzyme Q10 and vitamin C, alone or together, can improve healing and reduce dark gum color after surgical gum depigmentation. The trial involves 20 healthy adults with dark gums who undergo a simple scalpel procedure to remove pigmented tissue…

This early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…

This early-stage study tests a single dose of ABBV-519 in 30 adults with moderate lupus or rheumatoid arthritis. Researchers will check how the drug moves through the body, how it affects immune cells, and whether it is safe. Participants will be followed for about a year to moni…

This study tests a new tool called OPTIBIO that uses blood markers and patient data to help doctors decide if it's safe to reduce biological therapy in rheumatoid arthritis patients who are in remission. About 184 adults with RA in stable remission will be randomly assigned to ha…

This Phase 3 trial tests whether privosegtor, a neuroprotective drug, can improve vision recovery in people having their first episode of optic neuritis. About 210 adults aged 18 to 50 will receive either privosegtor or a placebo, both alongside standard steroid treatment. The ma…

This early-phase trial is testing a new treatment called KITE-363 for people with certain autoimmune nerve diseases that have not responded to standard therapies. KITE-363 is a type of CAR T-cell therapy that uses a patient's own immune cells, modified to target and attack faulty…

This early-stage trial tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy harmful immune cells. The study includes 120 people with relapsing or progressive multiple sclerosis or refractory myasthenia gravis. The main go…

This study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial ai…

This early-stage trial tests a new biologic drug called MER511 in 100 adults with Graves' disease. The main goal is to check safety and side effects, and to see how the body handles the drug when given by IV or injection. Participants must be on stable thyroid medication. The stu…

This study tests a drug called risankizumab in children with juvenile psoriatic arthritis, a condition causing joint pain and swelling. About 40 kids will receive either risankizumab or the standard drug adalimumab for 24 weeks, with responders continuing for up to 2 years. The g…

This study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…

This study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to …

This study looks at whether adding GLP-1 receptor agonists or SGLT inhibitors to insulin helps adults with type 1 diabetes manage their blood sugar better. Researchers will track 300 participants for one year, measuring changes in HbA1c and other health markers. The goal is to se…

This study tests whether BHV-1300 can help adults with Graves' disease achieve normal thyroid function without antithyroid drugs. Participants receive either BHV-1300 or a placebo via injection. The main goal is to see if more people on BHV-1300 have normal thyroid hormone levels…

This Phase 3 trial tests an oral drug called orelabrutinib against a placebo in about 990 people with non-active secondary progressive multiple sclerosis (MS). The goal is to see if the drug can delay worsening disability over 24 to 60 months. Participants are randomly assigned t…

This early-stage trial tests whether TIX100, a daily oral pill, is safe and tolerable in healthy adults who are overweight or obese. Over 28 days, participants receive either TIX100 or a placebo, and researchers monitor for side effects and how the drug moves through the body. Th…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This trial tests whether sirolimus (rapamycin), an immune-suppressing drug, can safely raise platelet counts in people with antiphospholipid antibodies and persistent low platelets. Participants are randomly assigned to receive sirolimus or a placebo for six months, and those who…

This study tests a new smartphone-based system that automatically delivers insulin for people with type 1 diabetes. Six adults who already use insulin pumps will try the system for a short time under close supervision. The goal is to see if the technology works safely and reliabl…

This study tests a treatment called VX-880 for people with type 1 diabetes who have dangerous low blood sugar episodes. The therapy uses donor cells that can produce insulin, aiming to let participants stop taking insulin shots and avoid severe hypoglycemia. About 52 adults with …

This study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…

This study tests a new gene therapy, PS-002, for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The therapy aims to control the disease in people who are at high risk of getting worse despite current treatments. Participants receive a single dose a…

This early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs…

This early-stage trial tests an experimental treatment called QEL-005 for people with two serious autoimmune conditions: diffuse cutaneous systemic sclerosis and difficult-to-treat rheumatoid arthritis. QEL-005 is made from a patient's own white blood cells, which are genetically…

This study tests whether montelukast, a common allergy medication, can lower protein levels in urine and improve kidney and blood vessel function in people with type 1 diabetes who have early signs of kidney disease. Inflammation is thought to play a role in diabetic kidney damag…

This study tests a new medicine called SBT777101 in 24 people with moderate-to-severe rheumatoid arthritis (RA). It is the first time this drug is given to humans, so the main goal is to check safety and side effects. Participants receive a single dose, and the dose is increased …

This study tests a medicine called anifrolumab for people with lupus who have not taken strong immune-suppressing drugs before. The goal is to see if the drug can help patients reach remission and reduce or stop their steroid use. About 245 adults will receive weekly injections f…

This study follows 630 people with type 1 diabetes in Japan who are already prescribed Awiqli, a once-weekly injection. Researchers will track side effects and blood sugar control over one year to see how the drug works in everyday life. The goal is to manage diabetes, not cure i…

This phase 3 trial tests whether the oral drug orelabrutinib can slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 705 adults aged 18–60 with PPMS will receive either orelabrutinib or a placebo for up to 5 years. The study measures ti…

This study tests an experimental drug called Afimkibart (RO7790121) in 160 people with moderate to severe rheumatoid arthritis who did not get better with or could not tolerate standard treatments like TNF or JAK inhibitors. Participants will receive either the drug or a placebo …

This study tests an experimental drug called IMC-002 (also known as IMM0306) in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial compares the drug against a placebo, both given alongside standard care, to see if it can reduce disease …

This study tests whether ublituximab, given as an infusion, can help adults with myasthenia gravis maintain symptom control after initial treatment with efgartigimod. Participants will receive either ublituximab or a placebo, and researchers will track how long it takes for sympt…

This study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare …

This study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …

This Phase 3 study tests whether the oral drug zasocitinib (TAK-279) can improve symptoms of active psoriatic arthritis in people who have never used biologic treatments. About 1,088 adults will receive either zasocitinib, an active comparator, or a placebo for up to 60 weeks. Th…

This early-stage study tests a new treatment called CHT101 for people with severe lupus that hasn't improved with standard treatments. CHT101 uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that drive lupus. The study will enroll 15…

This study tests a new medicine called tulisokibart for people with active psoriatic arthritis, a condition causing joint pain and skin plaques. Researchers will compare different doses of the drug to a placebo in 140 adults to see if it improves symptoms like joint tenderness an…

This study tests a new care model for 80 young adults with type 1 diabetes who are moving from pediatric to adult healthcare. The program includes a nurse educator, psychologist, and transition navigator working together to provide support over six months. The goal is to see if t…

This study tests an experimental drug called povetacicept in adults with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely reduces harmful immune proteins. About 30 participants will receive either the drug or a placebo,…

This early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…

This Phase 3 trial tests whether the experimental drug zasocitinib (TAK-279) can reduce joint swelling and pain in people with active psoriatic arthritis. About 600 adults will receive either the drug or a placebo for up to 60 weeks. The main goal is to see if more people on the …

This phase 3 trial is testing a new oral form of cladribine, a drug that calms the immune system, in 264 adults with generalized myasthenia gravis. Participants receive either low-dose cladribine, high-dose cladribine, or a placebo in two courses four weeks apart. The main goal i…

This study is testing the long-term safety and effectiveness of a drug called afimkibart in people with moderate to severe rheumatoid arthritis. Participants have already taken afimkibart in a previous study and will continue taking it. The goal is to see if the drug remains safe…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive eithe…

This study tests whether tofacitinib, a drug already used for rheumatoid arthritis, is safe and helpful for people with Sjogren's disease. About 60 adults with mild-to-moderate Sjogren's will take the pill twice daily for 28 weeks. Researchers will track side effects and measure …

This phase 3 trial is testing whether a daily pill called remibrutinib works as well as the standard infusion or injection ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40–70 who are stable on ocrelizumab will either switch to remibrutinib or sta…

This study follows 30 adults in Taiwan with relapsing-remitting multiple sclerosis who are starting fingolimod (Gilenya), a daily pill that helps control the disease. Over 12 months, researchers will watch for specific side effects like slow heart rate, vision problems, liver iss…

This study is testing whether stem cells taken from a person's own bone marrow and then given back through the veins and nose can improve brain and nerve function. It includes 500 people with various conditions like stroke, Parkinson's, Alzheimer's, and nerve damage. The goal is …

This early-stage trial is testing a new treatment called YTB323 for people with generalized myasthenia gravis that hasn't responded to standard therapies. YTB323 is a CAR-T cell therapy, meaning a patient's own immune cells are modified in a lab to better attack the disease. The …

This study tests an experimental drug called dapirolizumab pegol for people with moderate to severe lupus. About 450 participants will receive either the drug or a placebo, added to their usual treatments. The goal is to see if the drug can improve lupus symptoms over 48 weeks.

This study tests whether adding a new drug (RO7268489) to the standard MS treatment ocrelizumab can slow disability progression in adults with progressive multiple sclerosis. About 360 participants will receive either the new drug or a placebo, and researchers will track walking …

This phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …

This study tests whether baricitinib, a pill, can help preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes. About 300 children and young adults (ages 1 to under 36) will take either baricitinib or a placebo for 60 weeks. The goal is to see i…

This study tests an experimental oral drug called BI 3000202 in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of the drug or a placebo, taken daily for a year alongside their usual lupus treatments. …

This study tests a drug called pirtobrutinib in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The trial has two parts: first, finding safe doses, then comparing pirtobrutinib to a placebo to see if it ra…

This early-phase study tests whether combining mesenchymal stem cells (MSCs) with specially engineered immune cells (CAR-T cells) is safe and can help control autoimmune diseases. About 30 adults with established autoimmune conditions will receive the treatment and be monitored f…

This Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…

This phase 2 trial tests whether a 3-day course of high-dose corticosteroids (methylprednisolone or prednisone) can help heal ring-enhancing brain lesions in people with multiple sclerosis. Thirty adults with MS and a specific type of active lesion will be randomly assigned to re…

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…

This study tests an experimental drug called AZD1163 in 320 people with moderate-to-severe rheumatoid arthritis who haven't gotten enough relief from standard treatments. Participants receive either AZD1163 or a placebo as an injection, along with their usual care. The main goal …

This study tests whether anifrolumab, a drug that blocks certain immune signals, can improve blood vessel function and reduce inflammation in people with lupus. About 45 adults with lupus will receive either the drug or a placebo over 8 months. Researchers will measure changes in…

This trial tests a new drug called IMVT-1402 for adults with Graves' disease, a condition where the thyroid is overactive. The study will include 210 participants who still have high thyroid levels despite taking standard medications. Participants will receive either one of two d…

This study looks at whether a second islet transplant can safely improve blood sugar control in adults with type 1 diabetes whose first transplant stopped working. Researchers will follow 20 patients for up to 5 years, checking graft function, insulin use, and severe low blood su…

This study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…

This early-stage study tests a new drug called LY4213663 in healthy volunteers and people with rheumatoid arthritis (RA). The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug. The study lasts…

This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …

This Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …

This study tests an oral drug called iptacopan in people with generalized myasthenia gravis (gMG) who are already on standard treatment. About 146 adults will receive either iptacopan or a placebo for 6 months to see if it improves their ability to do daily activities and reduces…

This early-stage study tests an experimental drug called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants will receive either the drug or a placebo, and the study lasts …

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) who are over 40 and have been stable on strong anti-CD20 drugs for at least 3 years can safely switch to milder treatments. The goal is to see if this de-escalation approach prevents disease act…

This study follows 218 adults with systemic lupus erythematosus (SLE) in Italy who are starting anifrolumab (Saphnelo) for the first time. Researchers want to see if the drug helps patients reach a state of low disease activity while taking 5 mg or less of steroids daily. The stu…

This early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…

This phase 2 study tests two experimental drugs, lutikizumab and ravagalimab, alone or together, in about 180 adults with moderate-to-severe rheumatoid arthritis who have not improved with other treatments. The goal is to see if these drugs can reduce joint pain and swelling bett…

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and…

This study is testing a new blood filter called the Plasma Filter PX2. It is used in a procedure called therapeutic plasma exchange, which removes harmful substances from the blood of people with autoimmune diseases. About 46 adults will take part, and the study will check if the…

This study is tracking 125 adults with lupus who are starting a new drug called anifrolumab, given as a shot under the skin. Researchers want to see how many patients achieve remission (no active disease) after 24 months of treatment in real-world clinics, not just in strict rese…

This study tests whether a weekly under-the-skin antibody treatment (XEMBIFY) provides similar blood levels as a standard IV infusion (Gamunex-C) given every 3 weeks in people with CIDP, a chronic nerve disorder. About 40 adults who are stable on IVIG will first receive Gamunex-C…

This early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.

This study is testing a mobile app called Adhera Caring Digital Program for Obesity (ACDP-O) in 280 families. The app provides personalized education, mental health monitoring, and wearable device integration to support weight management and well-being in adolescents and young ad…

This Phase 3 study tests whether the drug remibrutinib can slow disability worsening in people with secondary progressive multiple sclerosis (SPMS). About 1,275 adults aged 18-65 with SPMS and recent disability progression will receive either remibrutinib or a placebo. The main g…

This study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …

This study compares two ways of giving the drug bimekizumab to people with active psoriatic arthritis or axial spondyloarthritis: as an IV infusion or as a shot under the skin. The goal is to see if the IV method works just as well as the shot. About 392 adults who are suitable f…

This study tests an experimental drug called GIA632 in 210 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the drug can safely restore skin color and to find the best dose for future studies. Participants will receive e…

This phase 2 trial tests whether ruxolitinib, a drug already approved for certain blood disorders, can help regrow hair in people with APECED, a rare immune condition that often causes severe alopecia areata. About 70 participants aged 12 to 75 will take the pill twice daily for …

This study tests a drug called bimekizumab in children aged 2 to 17 with specific types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). The goal is to see how the drug moves through the body and if it is safe. About 40 children will take par…

This early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…

This study tests if guselkumab can help people with Hailey-Hailey disease, a genetic condition causing painful blisters and sores in skin folds. Ten adults with moderate to severe disease will receive the drug and be monitored for changes in skin severity and quality of life. The…

This early-stage trial is testing a new drug called GSK4527363 in healthy volunteers and people with active lupus or lupus-related lung disease. The main goal is to check safety and how the body handles the drug. Around 142 participants will take part across four groups, includin…

This study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…

This observational study follows 50 adults with generalized myasthenia gravis who are new to complement inhibitors and are receiving ravulizumab (Ultomiris) in Poland. Researchers will track changes in daily living activities and other symptoms over time. The goal is to see how w…

This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see…

This study tests a drug called telitacicept in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo for 24 weeks to see if it improves daily activities and muscle strength. The goal is to control the…

This Phase 2 trial tests a drug called rezpegaldesleukin in people recently diagnosed with type 1 diabetes (within 100 days). The goal is to see if it can help the body keep producing some insulin, reducing the need for injected insulin. 66 participants will receive either the dr…

This study tests whether a 'treat-to-target' approach—where doctors adjust treatment every 6 weeks to aim for remission—works better than usual care for people with lupus. About 606 participants who are not in remission will be followed for 120 weeks. The goal is to see if this s…

This study tests whether changes in spinal fluid biomarkers can predict which drug or drug combination works best for people with progressive multiple sclerosis (MS). Participants will take one or two of five drugs (cilostazol, leucovorin, pirfenidone, dantrolene, or pioglitazone…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…

This study tests whether a non-invasive device that gently stimulates a nerve in the ear can help people with psoriatic arthritis. The device, called taVNS, is used for 20 minutes daily over 10 days. Researchers will measure changes in disease activity, pain, quality of life, and…

This early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…

This study tests if the drug sirolimus can help adults with lupus who also have very low platelet counts (a condition called immune thrombocytopenia). Participants will receive either sirolimus or a placebo for 24 weeks, then all will receive sirolimus for another 24 weeks. The g…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-stage trial tests a new medicine called VTP-1000 in 45 adults with celiac disease. The goal is to see if it is safe and how the body handles it, especially when exposed to gluten. Participants will receive either the drug or a placebo, and some will take a controlled g…

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and…

This phase 3 study tests anifrolumab, a biologic drug given by IV, in 100 children aged 5 to 18 with moderate to severe systemic lupus erythematosus (SLE). Participants continue their standard care and are randomly assigned to receive anifrolumab or a placebo. The goal is to see …

This study tests whether nicorandil, a drug usually used for heart conditions, can reduce inflammation and improve symptoms in people with active rheumatoid arthritis. 46 participants will take nicorandil tablets for 3 months. Researchers will measure joint disease activity and p…

This study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…

This study tests the long-term safety and effectiveness of an oral drug called zasocitinib (TAK-279) in adults with active psoriatic arthritis, a condition causing joint pain and skin patches. About 1,182 participants who completed a one-year parent study will take either a lower…

This study tests a drug called tafasitamab in adults with two rare autoimmune blood disorders: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The goal is to see if it can safely raise blood cell counts and reduce the need for other treatments. About 5…

This study tests a medicine called KIg 10 (intravenous immunoglobulin) in adults with chronic ITP, a condition where the immune system destroys platelets, causing bleeding and bruising. The goal is to see if KIg 10 can safely raise platelet counts and stop bleeding. About 40 peop…

This study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …

This study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…

This study tests an investigational drug called rozanolixizumab against a placebo in 120 adults with ocular myasthenia gravis, a condition causing eye muscle weakness like droopy eyelids or double vision. Participants receive the drug or placebo by injection, and researchers meas…

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 y…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This study tests a drug called ublituximab for people with a rare autoimmune disease that causes severe muscle weakness. The goal is to see if adding this drug to standard treatment improves muscle strength and function more than standard treatment alone. About 30 adults with ear…

This study tests a new approach for teens (ages 10-17) recently diagnosed with type 1 diabetes. They will use an inhaled insulin called Afrezza along with a long-acting injected insulin. The goal is to see if this combination helps keep blood sugar in a healthy range and is safe …

This early-phase study tests a new drug called OM336 in 39 adults with active Sjogren's disease or idiopathic inflammatory myopathy who have not improved with at least two prior treatments. OM336 is an engineered antibody designed to target and potentially reduce harmful immune c…

This study compares a continuous glucose monitor (CGM) to standard fingerstick testing in 270 adults with type 1 or type 2 diabetes who use insulin injections. Participants wear the Accu-Chek SmartGuide sensor to track blood sugar levels continuously. The goal is to see if the CG…

This early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic a…

This study tests whether betaine hydrochloride, a dietary supplement, can safely lower high gastrin levels in people with autoimmune gastritis. High gastrin is linked to an increased risk of stomach tumors. Sixty participants will receive either betaine or a placebo before meals …

This early-stage trial tests a new drug called TOP-N53, applied directly to finger ulcers in people with systemic sclerosis (scleroderma). The main goal is to check safety and see if it improves pain and blood flow. Fifteen participants will receive either the drug or a placebo o…

This study tests a daily pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that hasn't responded to standard treatments. AIHA is a condition where the immune system mistakenly attacks red blood cells, causing fatigue and anemia. The trial will enroll 50…

This study tests an investigational drug called IMVT-1402 in 231 adults with mild to severe generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it improves daily activities and muscle strength. The goal i…

This study tests whether a 12-week sleep-focused behavioral program can help adults with type 1 diabetes improve their sleep and blood sugar control. Participants learn sleep hygiene, stress management, and routines to target 7-9 hours of quality sleep. The study tracks sleep wit…

This Phase 3 trial tests whether mezagitamab, given as a shot under the skin, can safely keep platelet counts stable in adults with chronic ITP. ITP is a condition where the immune system destroys platelets, leading to easy bruising and bleeding. The study will compare mezagitama…

This phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …

This study is checking the long-term safety of guselkumab, a biologic drug given as a shot, in children with moderate to severe Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a prior guselkumab study and benefited from i…

This study is testing two drugs, efgartigimod and empasiprubart, given by IV, to see if they are safe and work well for people with myasthenia gravis (MG). The goal is to reduce side effects and improve quality of life. About 70 adults with MG are being recruited.

This study tests whether adding empasiprubart to the existing drug efgartigimod can improve symptoms and daily function in people with generalized myasthenia gravis who still have symptoms on efgartigimod alone. About 70 participants will receive both drugs intravenously. The mai…

This study tests a drug called soquelitinib in 15 people aged 16 and older with autoimmune lymphoproliferative syndrome (ALPS). The goal is to see if the drug can shrink an enlarged spleen or lymph nodes and improve low blood cell counts. Participants take the pill twice daily fo…

This study tests the drug belimumab (Benlysta) in 30 people who were diagnosed with lupus within the last two years. Participants will receive either the drug or a placebo for one year, and then some may switch to placebo in the second year. The goal is to see if early treatment …

This study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…

This study tests a drug called zasocitinib in adults with nonsegmental vitiligo, an autoimmune condition that causes white patches on the skin. About 200 participants will take either the drug or a placebo for up to a year. The main goal is to see if the drug can improve skin col…

This trial tests whether adding rituximab to standard mycophenolate mofetil (MMF) therapy can improve lung function in people with severe lung scarring caused by systemic sclerosis. About 102 adults with this condition will receive either rituximab infusions plus MMF or placebo i…

This early-stage study tests a new treatment called RN1201 for people with certain blood disorders caused by the immune system attacking the body's own cells. The treatment involves giving patients specially designed immune cells after a short course of chemotherapy to weaken the…

This study is testing whether a portable gluten-detection device, combined with regular telemedicine check-ins with a dietitian, can improve gut healing in adults newly diagnosed with celiac disease. Two hundred participants will use the technology and receive expert guidance to …

This early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …

This study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…

This study tests a new drug called sonelokimab for adults with active psoriatic arthritis who have not improved with or cannot take standard TNF-blocker medications. About 600 participants will receive either sonelokimab, a placebo, or an existing drug (risankizumab) for comparis…

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This study looks at whether a plant-based (vegan) diet can help children with autoimmune hepatitis achieve disease remission. Researchers will compare a vegan diet to a standard high-protein diet over 180 days in 40 newly diagnosed children. The goal is to see if diet changes can…

This study tests a one-time treatment called CABA-201, made from a patient's own immune cells, for people with active inflammatory muscle diseases like dermatomyositis. The therapy aims to reset the immune system by targeting and removing certain immune cells. Researchers will ch…

This early-stage study is testing whether an oral probiotic called R-2487 is safe for people with rheumatoid arthritis. Researchers will also check if it reduces joint swelling and inflammation. The trial involves 73 adults with active RA who will take the probiotic and be monito…

This study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…

This study looks at whether adding tirzepatide (a weight-loss drug) to standard ixekizumab treatment helps adults with active psoriatic arthritis who are overweight or obese. About 200 participants will receive both medications for up to 12 months. The goal is to see if this comb…

This study tests whether a steroid mouthwash (clobetasol propionate 0.05%) and low-level laser therapy, alone or together, can heal painful mouth sores in people with pemphigus vulgaris—a chronic autoimmune disease that causes blisters on skin and mucous membranes. Thirty partici…

This study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…

This study compares the iLet Bionic Pancreas, an automated insulin delivery system, to standard care for adults with type 1 or type 2 diabetes who use insulin. About 240 participants will use the device for 13 weeks or continue their usual routine. The goal is to see if the devic…

This study tests a drug called teplizumab in people aged 1 to 25 who were recently diagnosed with type 1 diabetes. The goal is to see if teplizumab can help control blood sugar and reduce the need for insulin at mealtimes. Participants will receive either teplizumab or a placebo …

This study tests whether a second course of ianalumab can help adults with two rare blood disorders—immune thrombocytopenia (ITP) and warm-antibody autoimmune hemolytic anemia (wAIHA)—who previously responded to the drug but then stopped responding. About 60 participants will rec…

This study tests whether adding roflumilast to standard treatment can reduce joint pain and swelling in people with active rheumatoid arthritis. About 50 adults aged 18-60 will take either roflumilast or a placebo for 12 weeks. Researchers will measure changes in disease activity…

This study tests a digital tool that helps children under 12 with type 1 diabetes calculate their insulin doses. The tool considers factors like carbs, blood sugar levels, and trends. Researchers will compare blood sugar control (HbA1c) over 6 months between kids using the tool p…

This study is checking if a new insulin pump (NMX8) and continuous glucose monitor (DS5/Simplera Sync) are safe for people with type 1 or type 2 diabetes. About 400 participants, ages 7 to 85, will first wear the sensor for up to 40 days, then use the pump for about 90 days while…

This study tests an oral drug called fenebrutinib in 12 children and adolescents aged 10 to 17 with relapsing multiple sclerosis. The goal is to see how the drug moves through the body, how safe it is, and whether it reduces new brain lesions seen on MRI. Participants can choose …

This study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …

This study tests whether combining two drugs—ofatumumab and daratumumab—can safely and effectively treat people with severe anti-NMDAR autoimmune encephalitis, a condition where the immune system attacks the brain. The drugs aim to eliminate the harmful immune cells producing the…

This phase 2 trial is testing whether adding desloratadine, an allergy medication, to standard rheumatoid arthritis therapy can reduce joint inflammation and disease activity. Sixty adults with active RA will receive either desloratadine or a placebo for 12 weeks. The study measu…

This study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…

This early-phase study tests whether dichloroacetate (DCA), a drug used safely for decades in a rare metabolic disorder, can improve brain function during low blood sugar (hypoglycemia) in people with type 1 diabetes. Sixteen participants with a history of severe hypoglycemia or …

This early-stage study is testing a new insulin pill (SCD0503) in 16 men with type 1 diabetes. The goal is to see how well the pill works compared to standard injected insulin and whether it is safe. Participants will have their blood sugar carefully controlled during the study t…

This early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.

This study follows 50 people who receive a Zimmer Biomet shoulder replacement implant to see if it safely improves pain, movement, and quality of life over two years. Participants have shoulder arthritis, fractures, or other joint damage. The main goal is to measure a meaningful …

This early-phase trial is testing a new drug called BMS-986454 in 46 adults with rheumatoid arthritis who did not fully respond to methotrexate. The main goal is to check the drug's safety, tolerability, and how it moves through the body. Participants will receive either the drug…

This Phase 3 study tests whether telitacicept, a biologic drug given as a shot, can reduce disease activity in adults with active primary Sjögren's disease. About 250 participants will receive either telitacicept or a placebo for 48 weeks. The main goal is to see if the drug impr…

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which reduces harmf…

This early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…

This Phase 3 study tests whether the drug mavorixafor can reduce serious infections and increase neutrophil levels in people with chronic neutropenia—a condition where the body doesn't make enough infection-fighting white blood cells. About 176 participants will receive either ma…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early-phase trial tests Arnovie101, an mRNA-based CAR-T therapy given directly into the bloodstream, in 5 people with lupus or autoimmune hemolytic anemia. The goal is to see if it is safe and how the body processes it. Researchers will also check if it reduces disease activ…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This study looks at whether using a positive airway pressure (PAP) machine at night can improve thinking, sleepiness, and quality of life in older veterans (age 60+) who have both COPD and obstructive sleep apnea—a combination called Overlap Syndrome. About 668 participants will …

This early-stage trial tests a new drug called NNC0497-0040 in healthy people, those with overweight or obesity, and people with type 1 diabetes who are also overweight. The goal is to see if the drug is safe and tolerable when given as a weekly injection. About 146 participants …

This study tests a drug called efgartigimod in 12 children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and see if it is safe. Participants receive injections and are monitored for up to 14 weeks.

This study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…

This study tests whether the drug ianalumab can help people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and can damage internal organs like the lungs. About 200 adults will receive either ianalumab or a placebo as a shot under the skin. Rese…

This study tests whether the experimental drug JNJ-88545223 can reduce joint pain, swelling, and skin symptoms in adults with active psoriatic arthritis. About 240 participants will receive either the drug or a placebo to see if it works better than no treatment. The goal is to i…

This study tests an oral drug called rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. About 90 adults who have not responded well to steroids will receive either rilzabrutinib or a placebo for 24 weeks, follo…

This study tests whether a new drug called EI-001 can help people with vitiligo, a condition that causes white patches on the skin. The drug works by calming the immune system to reduce inflammation. About 45 adults with nonsegmental vitiligo will receive either EI-001 or a place…

This study tests a drug called guselkumab in 100 Indian adults with psoriatic arthritis, a condition causing joint pain and swelling. Participants must have tried standard treatments without success. The goal is to see if the drug is safe and helps reduce joint symptoms over 12 w…

This study is testing how well the drug guselkumab works for people with psoriatic arthritis, a condition that causes joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 participants over 24 weeks. The goal is to see if guselkumab red…

This study tests an experimental drug called MTX-474 in 85 people with diffuse cutaneous systemic sclerosis, a condition that causes skin thickening and organ damage. Participants will receive either MTX-474 or a placebo for 24 weeks to see if the drug safely reduces skin thickne…

This study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-w…

This phase 3 study tests whether nipocalimab can help control moderate to severe systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 600 adults will receive either nipocalimab or a placebo, on top of standard treatments. The main goal is to see if more people …

This study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug reduces joint pain and skin symptoms better than a …

This early-phase trial is testing a new treatment called GC012F (CD19-BCMA CAR-T cells) for people with severe lupus that hasn't improved with standard medications. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells driving the disease. T…

This study tests the safety of an experimental drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections of the drug for up to 52 weeks, alongside …

This early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…

This study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …

This early study tests a new treatment called IASO207 for people with active lupus that hasn't responded to standard therapies. The treatment works by creating special immune cells inside the body to target and calm the overactive immune system. The study will check if it's safe …

This study follows 1,000 patients with autoimmune or inflammatory conditions who have already completed a Novartis trial with secukinumab and are judged to benefit from continued treatment. Participants receive secukinumab injections to monitor long-term safety, including side ef…

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…

This study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…

This early-phase trial is testing a new drug called DB-2304 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. About 148 participants will receive either DB-2304 or a placebo. This is a first step to see…

This study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…

This study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.

This study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …

This study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damag…

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This study is testing a drug called secukinumab, given as an IV infusion, in 20 children aged 2 to 17 with juvenile psoriatic arthritis. The main goals are to see how the drug moves through the body and to check its safety over up to 6 years. This is an early-stage trial, so it f…

This study tests an experimental pill called cadisegliatin taken alongside insulin in adults with type 1 diabetes. The goal is to see if it can lower the number of dangerously low blood sugar events (hypoglycemia) without worsening overall blood sugar control. About 150 participa…

This study is testing a new tool called MODI, which is a smart algorithm that helps people with diabetes figure out the right amount of insulin to take. About 100 adults with type 1 or type 2 diabetes will use the MODI system along with a continuous glucose monitor for 13 weeks. …

This Phase 3 study tests whether remibrutinib can improve daily function in adults with generalized myasthenia gravis, a condition that causes muscle weakness. About 180 participants will receive either the drug or a placebo for 6 months, followed by an open-label phase where eve…

This study tests whether giving a low dose of anti-thymocyte globulin (ATG) followed by either adalimumab or verapamil can help preserve the body's ability to make insulin in people aged 9 to under 21 who were recently diagnosed with type 1 diabetes. The main goal is to see if th…

This early-stage trial tests a single injection of JADE201 in 36 adults with rheumatoid arthritis. The main goal is to check safety and how the body processes the drug. Participants receive either JADE201 or a placebo, and researchers monitor side effects and drug levels in the b…

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This phase 2 study tests whether giving emapalumab or a combination of fludarabine and dexamethasone before a stem cell transplant can reduce inflammation and help the donated cells take hold better. The trial involves 39 people with primary immune regulatory disorders or autoinf…

This study is testing whether semaglutide, a drug already used for type 2 diabetes, can reduce kidney damage in people with type 1 diabetes and diabetic kidney disease. About 60 adults will receive either semaglutide or a placebo for 26 weeks. Researchers will measure changes in …

This study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The main goals are to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. The drug is g…

This study tests two types of engineered immune cells (CAR T cells) in 40 adults with active pemphigus vulgaris, a painful blistering skin condition. The cells are designed to target and reduce the faulty immune cells that attack the skin. The main goal is to check safety and fin…

This study tests a new drug called SAB-142 in people recently diagnosed with type 1 diabetes. The goal is to see if it can help the body keep making its own insulin for longer, slowing the disease. About 159 people aged 5 to 40 will receive either the drug or a placebo, and resea…

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…

This early-stage trial is testing a new drug called IASO-782 in 16 adults with autoimmune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). These conditions cause the immune system to mistakenly attack blood cells. The study's main goal is to check the drug's sa…

This early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…

This early-stage trial is testing a new drug called SHR-2173 for people with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study will enroll 10 adults to check the drug's safety and how well it works. Particip…

This study tests a single dose of tanruprubart (ANX005) in 30 adults and children with Guillain-Barré syndrome (GBS), a rare nerve disorder that causes weakness. The goal is to see how the drug works in the body, its early effects, and its safety. Participants must have GBS sympt…

This study tests a weekly injection called romiplostim in 60 adults with immune thrombocytopenia (ITP) whose platelet counts stayed low despite oral medications. The goal is to see if the shot can safely raise platelet levels and reduce bleeding over 24 weeks. Participants stop t…

This early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…

This early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…

This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…

This study tests whether tirzepatide, a weekly injection already used for type 2 diabetes, can help adults with type 1 diabetes use an automated insulin pump without needing to count carbohydrates at meals. About 105 participants will be randomly assigned to receive tirzepatide o…

This study tests the drug ocrelizumab in 60 Chinese adults with two forms of multiple sclerosis (MS): relapsing MS and primary progressive MS. The goal is to see if it reduces relapses and controls disease activity. Participants receive ocrelizumab infusions, and researchers trac…

This early-stage trial tests an injectable drug called GL-2045 in 42 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The goal is to see if GL-2045 can safely raise platelet counts like standard IVIg therapy…

This study follows 1,000 people with Stage 2 Type 1 Diabetes who have received teplizumab in routine care. Researchers will track how long it takes for the disease to progress to Stage 3 and assess quality of life. The goal is to see if teplizumab delays the need for insulin ther…

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive the drug as a shot under the skin. The main goal is to see if it improves their ability to do daily activities after ab…

This study tests a new drug called CIT-013 in 88 adults with moderately active rheumatoid arthritis. Participants will receive either CIT-013 or a placebo every two weeks for six weeks. The goal is to see if CIT-013 reduces joint swelling and pain better than a placebo, and to ch…

This study is monitoring the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. Researchers will track side effects and disease activity over 24 weeks. About 2,040 participants are being observed during r…

This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…

This phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …

This study tests whether a supplement called 2-HOBA can help people with lupus by lowering blood pressure and reducing harmful immune activity. About 42 women with stable lupus and mild-to-moderate high blood pressure will take either 2-HOBA or a placebo for 8 weeks, then switch.…

This early-stage study tests a new drug called SAR448501 (DR-0201) in 62 adults with lupus or rheumatoid arthritis. The drug is a bispecific antibody designed to target the immune system. The main goal is to check safety and find the right dose, not yet to prove it works. Partici…

This phase 2 trial tests two doses of rilzabrutinib, an oral drug, in 30 adults with Graves' disease (with or without eye problems). The main goal is to see if the drug lowers high thyroid hormone levels over 16 weeks. Researchers will also monitor safety and side effects.

This phase 2b trial tests an experimental drug called IMVT-1402 in 240 adults with Graves' disease whose thyroid is still overactive despite standard treatment. The goal is to see if the drug can help patients achieve normal thyroid hormone levels and stop taking antithyroid medi…

This study compares muscle thickness around the shoulder blade in people with early ankylosing spondylitis (an inflammatory condition) versus those with mechanical shoulder blade movement problems. Researchers use ultrasound and electromyography (EMG) to see if they can tell the …

This study tests whether using an AI-driven retinal camera during regular diabetes checkups can increase the number of young people screened for diabetic retinopathy, a leading cause of blindness. Researchers will enroll 500 youth with type 1, type 2, or cystic fibrosis-related d…

This early study tests a single oral dose of HB-2121 in 20 adults with suspected celiac disease. The dye is given four hours before a standard endoscopy to see how it interacts with the small intestine and whether it is safe. Researchers will track side effects and measure the dy…

This study tests whether a tablet-based eye-tracking app (eVOG) can detect subtle eye movement problems in people with brain MRI abnormalities (white matter lesions). The goal is to see if these eye movement patterns can help diagnose multiple sclerosis or related conditions. Res…

This Canadian study tests whether adding two questions about morning stiffness and lower back pain to a standard screening tool (PEST) can help dermatologists identify psoriatic arthritis earlier in people with moderate-to-severe plaque psoriasis. About 502 adults who are candida…

This study tests a software called Glandy HYPER that uses artificial intelligence to detect thyrotoxicosis—a dangerous overactive thyroid state—in people with Graves' disease. The AI analyzes resting heart rate data from wearable devices like smartwatches and compares it with sta…

This study is testing a new real-time continuous glucose monitoring (CGM) system to see how accurate and safe it is for adults with type 1 diabetes. About 82 participants will wear the device, and its readings will be compared to standard lab measurements. The goal is to improve …

This study is testing a new scoring system called OC26 to help doctors more accurately diagnose autoimmune pancreatitis, a condition where the immune system attacks the pancreas. Researchers will review medical data from 82 adults suspected of having the disease. If the OC26 crit…

This study tests whether the drug baricitinib can delay the onset of type 1 diabetes in children aged 1 to 36 months who are at high risk. Participants take baricitinib or a placebo daily for up to 5 years. The goal is to see if the drug can push back or prevent the need for insu…

This study tests whether people with multiple sclerosis can learn to prevent falls by practicing on a treadmill that unexpectedly slips or trips. 64 participants aged 45 and older will be split into two groups: one gets the slip-and-trip training, the other just walks on the trea…

This study tests whether using a carotid ultrasound (a neck scan) to find hidden plaque in arteries can help prevent heart attacks and strokes in people with inflammatory rheumatic diseases like rheumatoid arthritis or lupus. About 1,944 participants aged 50 and older will be spl…

This study tests whether adding music-like sounds (sonification) to standard walking rehabilitation can improve gait, balance, and quality of life. 120 adults with Parkinson's disease, stroke, or multiple sclerosis will be randomly assigned to standard rehab or rehab with sonific…

This study tests whether exercise paired with simple mental tasks (like counting backwards) can improve walking, balance, and thinking in people with multiple sclerosis. Forty adults with MS will do supervised workouts twice a week for 8 weeks. The goal is to find better rehab st…

This study compares three different diets to see which one best reduces bloating and other stomach symptoms in people with systemic sclerosis (scleroderma). Sixty participants will follow one of three diets for six weeks: a low-FODMAP diet, a diet that removes foods harmful to th…

This study tests whether a noninvasive brain stimulation technique called tDCS can reduce depression in people with multiple sclerosis. Participants use a headband-like device at home for 30 minutes a day over 30 days, while listening to mindfulness meditation. Half receive real …

This early-phase trial tests whether injecting mesenchymal stromal cells (MSCs) into the salivary glands is safe and can ease dry mouth in people with graft-versus-host disease or Sjogren's disease. Up to 36 adults will receive one injection and be monitored for pain and side eff…

This early-phase study tests a 4-week training program that uses mixed reality to guide precise movements, like stacking virtual objects. The goal is to see if this can improve walking speed, balance, and thinking in people with multiple sclerosis. Thirty adults with MS will part…

This study tests whether a protein-based eye drop (rhPRG4) can safely relieve dry eye symptoms in people with Sjögren's syndrome. About 80 adults will receive either the active drops or a placebo for 28 days. The main goal is to see if the drops can clear corneal staining, a sign…

This pilot study tests whether a new, faster radiation planning method can safely ease severe abdominal pain caused by advanced cancer. Instead of a separate planning session, doctors use existing scans to create a treatment plan on the spot. Only 5 people will take part, and the…

This study looks at whether changing what you eat can help with rheumatoid arthritis. 66 adults with RA will follow either a gluten-free diet, a Mediterranean diet, or their usual diet for 12 weeks. Researchers will measure disease activity, quality of life, and inflammation to s…

This study tests whether cognitive behavioral therapy for insomnia (CBT-I) can improve sleep and reduce fatigue in people with multiple sclerosis. About 70 adults with MS and insomnia will receive CBT-I or an active control. The goal is to see if this talk therapy approach can ea…

This study tests whether a single nerve block injection (erector spinae plane block) can reduce persistent back pain in people with ankylosing spondylitis whose disease activity is already controlled by medication. Fifteen adults aged 18–65 will receive the injection and be monit…

This study tests an experimental oral drug, BMS-986368, for treating muscle stiffness (spasticity) in people with multiple sclerosis. About 200 participants will receive one of three doses of the drug or a placebo. The goal is to see if the drug safely reduces muscle tightness an…

This study tests whether solriamfetol (Sunosi), a drug used for sleepiness, can reduce fatigue in people with multiple sclerosis who also have excessive daytime sleepiness. About 46 participants will receive either the drug or a placebo for four weeks, then switch after a washout…

This study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…

This study looks at whether two different exercise programs can help reduce depression in people with multiple sclerosis (MS) who also have major depressive disorder. Researchers will enroll 146 adults aged 18 to 64. One group will do a structured exercise program, while the othe…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study tests whether pairing teens with type 1 diabetes with a young adult peer mentor can help them become more physically active and improve their quality of life. The 12-week program includes in-person, virtual, and text-based support. Researchers will measure how well the…

This study tests whether silodosin, a drug typically used for enlarged prostate, can help women with multiple sclerosis who have bothersome urinary symptoms. Sixty female participants will take either silodosin or a placebo daily for 8 weeks. Researchers will use symptom question…

This study tests a group-based program called Supporting Teen Problem Solving (STePS) designed to reduce diabetes-specific emotional distress in teenagers with type 1 diabetes. The program is based on cognitive-behavioral and problem-solving approaches. Researchers will enroll 36…

This study compares a psychological therapy program called ACT1VATE to standard diabetes education in 250 adults with type 1 diabetes who have high emotional distress and poor blood sugar control. The therapy is delivered in five group sessions via video call. Researchers will me…

This study tests whether dry needling—a treatment using thin needles to target tight muscles—can reduce chronic lower-limb pain in people with multiple sclerosis. Twenty-four participants will receive either real or sham dry needling over six sessions. Researchers also hope to se…

This long-term observational study uses MRI scans to track how multiple sclerosis (MS) changes over time in up to 3750 people. Researchers will compare brain images and immune system markers in untreated patients, those on approved therapies, and healthy volunteers. The goal is t…

This study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …

This study is looking for the genes that cause certain immune system problems. Researchers want to understand why some people get sick and others don't, even in the same family. Up to 5,000 people with immune disorders and their relatives will give blood or cheek cell samples for…

This study will analyze DNA from up to 20,000 people, including those with immune disorders and their relatives, to find genetic variants linked to conditions like atopy, autoimmunity, and primary immunodeficiency. Researchers will also study how best to return genetic results to…

This study aims to uncover genetic changes that cause autoimmune diseases in people native to Peru. Researchers will collect blood, urine, and stool samples from 300 participants, including patients with conditions like lupus and rheumatoid arthritis, their family members, and he…

This study investigates whether the bacteria causing Lyme disease can survive antibiotic treatment and cause ongoing symptoms. Researchers will follow 700 participants, including those with chronic Lyme disease, recovered individuals, and healthy volunteers, using blood tests, sp…

This observational study is recruiting 2400 people with immune-related central nervous system diseases, such as multiple sclerosis, along with healthy volunteers for comparison. Researchers will use MRI scans, lumbar punctures, blood tests, and neurological exams to track disease…

This study follows 900 people with bronchiectasis—a condition where airways are damaged and prone to infection—to learn why they get sick repeatedly. Researchers will collect medical history, lung function tests, and blood, urine, and sputum samples from patients and their family…

This study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…

This study aims to find the genetic causes of inherited immune problems that affect white blood cells called lymphocytes. Researchers will review medical records and collect blood samples from up to 5,000 people with suspected immune disorders, as well as their relatives. The goa…

This study looks at how improving sleep regularity might help control blood sugar and reduce heart disease risk in adults with type 1 diabetes. Researchers will monitor 100 participants' sleep, blood sugar, and heart health markers. The goal is to understand the body clock's role…

This study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …

This study follows people with autoimmune lymphoproliferative syndrome (ALPS) and their relatives over many years. Researchers will collect blood and tissue samples, track symptoms, and study genetics to better understand why the immune system attacks the body. The goal is to lea…

This study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…

This study looks at basic blood and clotting measures in children with type 1 diabetes compared to healthy children. Researchers want to see if diabetes causes changes in red blood cells or clotting that could lead to complications. The study involves children aged 1 month to 18 …

This study follows up to 2,000 people with spondyloarthritis (a group of inflammatory joint and spine conditions) and their healthy relatives. Researchers aim to identify symptoms, genetic factors, and medical tests that predict who will develop more severe forms of the disease. …

This study looks at skin problems that appear during a COVID-19 infection, with a special focus on chilblains (painful red or purple bumps on fingers or toes). Researchers want to understand why these skin changes happen—whether from the virus itself, tiny blood clots, or inflamm…

This study follows people who previously took part in type 1 diabetes trials to see how long their bodies continue to produce insulin. Researchers will also look at how immune system changes relate to insulin production. The goal is to gather information that could lead to better…

This study aims to better understand disorders that cause hearing to fluctuate, such as Meniere's disease. Researchers will use advanced MRI scans and blood tests to look for biomarkers linked to hearing changes. The goal is to identify different types of these disorders and pave…

This study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…

This study is tracking 500 pregnant women with lupus to see if the drug anifrolumab is linked to birth defects or pregnancy loss. Researchers will compare women who took anifrolumab during early pregnancy to those who did not. The goal is to gather real-world safety data, not to …

This study is gathering blood, stool, and skin samples from 100 adults with systemic sclerosis to learn more about the disease. Researchers will also track health information like skin thickness, lung function, and quality of life over time. The goal is to build a biobank for fut…

This study looks at gum disease in people with rare kidney disorders like Alport syndrome, Fabry disease, and tuberous sclerosis, as well as lupus. Researchers will compare 100 participants to those with chronic kidney disease and healthy controls. They aim to understand how comm…

This study is looking at how well current classification criteria can diagnose primary Sjögren's syndrome, a rare autoimmune disease. Researchers will compare the criteria against diagnoses made by expert doctors. The goal is to improve diagnostic accuracy for this condition.

This study is measuring a protein called STIM1 on the surface of immune cells in 670 people with various autoimmune diseases. The goal is to find which diseases have high levels of this protein, which could help researchers develop new antibody-based treatments. Participants prov…

This study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.

This study is analyzing inflammatory markers in the blood and spinal fluid of 300 people who are being checked for multiple sclerosis (MS). The goal is to see if certain markers can help doctors tell MS apart from other autoimmune diseases that affect the brain and spinal cord. R…

This study is testing a new device called BloodTrackR that lets people with rheumatoid arthritis collect a small blood sample at home using a finger prick and a smartphone app. Twenty participants will try the device and answer questions about how easy it is to use. The goal is t…

This study follows 700 people with progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus. Researchers will collect blood, spinal fluid, and brain scans over time to understand how the disease progresses. No treatment is given; the goal is…

This study follows 300 adults with systemic lupus erythematosus (SLE) who are seen by a team of specialists at a hospital in Brest, France. Researchers will collect data on disease patterns, symptoms, and test results over time. The goal is to better understand lupus and improve …

This study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…

This study is looking for biological markers (biomarkers) in blood, saliva, and urine that signal damage to insulin-producing beta cells in the pancreas. Researchers will compare samples from people with type 1 diabetes, type 2 diabetes, prediabetes, and healthy volunteers. The g…

This study looks at whether certain genes make some people more likely to develop eye damage from the drug Plaquenil, which is used for autoimmune diseases like lupus and rheumatoid arthritis. Researchers will compare people who have had eye damage from Plaquenil with those who h…

This study follows 442 pregnant women with moderate-to-severe lupus to see if taking the drug anifrolumab (Saphnelo) during pregnancy affects the health of mothers or their babies. Researchers will compare women who took the drug during pregnancy to those who did not, tracking bi…

This study is testing a new device that combines an insulin pump with a continuous glucose monitor in one unit for adults with type 1 diabetes. The goal is to see how insulin delivery near the sensor affects glucose readings and to gather data to improve the design. About 40 part…

This study is observing 40 adults with multiple sclerosis to see how clinical tests of balance and walking relate to detailed motion-capture measurements. Participants will attend one session where they walk on force plates and perform balance tasks while cameras track their move…

This study aims to create a smartphone system that sends personalized pain management tips to adults with multiple sclerosis or spinal cord injury who have chronic pain. Researchers will interview participants to understand their preferences for the content and timing of these no…

This study looks at whether sulfasalazine, a drug for inflammatory arthritis, makes the standard diabetes blood test (HbA1c) falsely low. That could mean diabetes goes undiagnosed or is undertreated in these patients. Researchers will use continuous glucose monitors and fasting b…

This study is collecting joint fluid and tissue samples from 50 adults with inflammatory or non-inflammatory bone and joint diseases. Researchers will use both standard and advanced lab techniques to find new biomarkers that could help diagnose rheumatic diseases more accurately …

This study from Mayo Clinic looks at how one session of exercise changes breastmilk. Researchers will measure tiny particles called exosomes that carry messages between cells. They want to see if exercise boosts these particles in breastmilk, which might help prevent childhood ob…

This study watches over 3,000 adults with moderate-to-severe lupus to see if the drug anifrolumab increases the risk of serious infections or cancer compared to standard treatments. No new medicine is given—researchers simply analyze health records from people already prescribed …

This trial is studying a medical device that has not been approved by the U.S. FDA. The purpose and specific details are not publicly available. It likely involves a small group of participants to gather initial safety or effectiveness data.

This study will give 100 adults with diabetes a thermal camera that attaches to their smartphone to take daily pictures of their feet. The goal is to collect temperature data and see if hot spots can predict where foot ulcers might form. Participants will use the device at home f…

This study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…

This study is looking for clues to predict how well different rheumatoid arthritis (RA) drugs will work in individual patients. Researchers will give 400 adults with RA one or more standard medications and track their response over 16 weeks. The goal is to find genetic or other f…

This study aims to find new genes that cause immune system problems by examining up to 500 people with immune disorders and their relatives. Participants provide blood, saliva, or tissue samples and may have medical tests, but no experimental treatments are given. The goal is to …

This study is testing whether monthly blood tests for a nerve damage marker (neurofilament light chain) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (MS) earlier than standard yearly MRI scans. The goal is to reduce the need for gadolin…

This study follows 300 people with Sjogren's disease (or symptoms) over time to learn how the condition starts and progresses. Participants undergo exams, saliva and tear tests, and questionnaires during several visits. No treatment is given; the goal is to gather data and sample…

This study follows 100 women with neuroimmune diseases (like multiple sclerosis or myasthenia gravis) through pregnancy and up to five years after. Researchers will track disease activity, pregnancy complications, and baby health to learn how these conditions affect fertility and…

This study reviews the medical records of 100 adults who were treated for Guillain-Barre Syndrome (GBS) at a single hospital in Switzerland. The goal is to better understand how often GBS occurs, what symptoms and nerve problems people have, what treatments they receive, and how …

This study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …

This study aims to understand why some people get severe or unusual fungal infections due to immune system problems. Researchers will collect blood, tissue, and other samples from up to 1,200 participants over 25 years. No new treatments are being tested; the goal is to learn mor…

This registry study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI (ublituximab-xiiy) in real-world settings. Researchers aim to track safety, effectiveness (like relapse rates), and the overall treatment experience. Participants must not hav…

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatm…

This registry study follows pregnant women with multiple sclerosis (MS) who have taken BRIUMVI, comparing them to those who haven't taken the drug. The goal is to see if BRIUMVI increases the risk of major birth defects. Researchers will enroll about 728 participants across two g…

This study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …

This study examines how spinal posture and movement relate to balance in 30 adults with relapsing-remitting multiple sclerosis. Researchers will measure spinal angles and mobility, then compare them with balance tests. The goal is to identify links that could inform future rehabi…

This study follows 50 adults with generalized myasthenia gravis who are taking Rozanolixizumab. Researchers want to see how the drug affects symptoms like fatigue and muscle weakness from the patient's own point of view. Participants will fill out a special questionnaire over 9 m…

This registry follows pregnant women who have taken mycophenolate, a drug used to prevent organ rejection and treat autoimmune diseases. Researchers will collect data on pregnancy complications and birth defects up to one year after birth. The goal is to better understand the dru…

This observational study is gathering detailed metabolic data from 25 adults with insulin-dependent type 2 diabetes. After drinking a standard liquid meal, participants will have frequent blood tests to measure glucose, insulin, and other markers. They will also wear continuous g…

This study watches how doctors in Russia treat adults with a rare muscle-weakening disease called generalized myasthenia gravis (gMG). It does not test any new drug. Instead, it collects information from medical records and routine check-ups for about 450 people over time. The go…

This study looks at how blood sugar changes day-to-day in people with ketosis-prone diabetes as they go into remission. Researchers will use this data to build a math model that describes the remission process. The study involves 12 African American adults with a BMI of 28 or hig…

This study looks at how menstrual cycles and birth control pills impact blood sugar levels and exercise in women with type 1 diabetes. Researchers will monitor 150 women for three months using continuous glucose monitors and offer personalized insulin and diet adjustments. The go…

This observational study follows 170 people with multiple sclerosis, neuromyelitis optica, and similar conditions, plus healthy volunteers, for up to 6 years. Researchers use MRI scans, blood tests, and spinal fluid analysis to monitor brain lesions and understand how the disease…

The CLUE study is a research project that follows 1,000 people with neuroinflammatory diseases like multiple sclerosis and neuromyelitis optica. Participants undergo detailed MRI and PET scans at the start and after one year to see how their brain, spinal cord, and optic nerves c…

This study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …

This study collects information from 10,000 adults who have had hip or knee replacement surgery at Heidelberg University Hospital. Researchers will follow participants during routine check-ups to see how long the artificial joints last, how well they function, and what problems m…

This study looks at whether special breathing exercises can help the brains of people with multiple sclerosis or cancer, as well as their caregivers. Researchers will use MRI scans to see how breathing affects oxygen flow in the brain. The goal is to understand the connection bet…

This study investigates whether certain environmental exposures—like infections, stress, or sun exposure—are more common in people with anti-synthetase syndrome, a rare autoimmune condition that causes muscle weakness and lung disease. Researchers will compare 580 participants, i…

This study looks at 20 adults with psoriatic arthritis and fatty liver disease to see if the drug guselkumab can improve liver fat, joint swelling, and skin plaques. Participants will have two visits over 24 weeks to track changes. The goal is to understand shared disease mechani…

This study follows 160 people with relapsing multiple sclerosis in Greece who are already taking ofatumumab (Kesimpta®) as part of their routine care. Researchers will track how many patients have no signs of disease activity—like relapses, new brain lesions, or worsening disabil…

This study looks at whether smartwatches can help monitor chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disease that causes weakness and numbness. 35 adults with CIDP who use subcutaneous immunoglobulin therapy at home will wear a smartwatch for 12 months…

This study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…

This study looks at how accurate continuous glucose monitors (CGMs) are in children and young adults with type 1 diabetes when they have surgery. Researchers will compare CGM readings to standard blood glucose tests during the procedure. The goal is to see if these devices can be…

This study looks at whether a special nursing care model helps people with long-term health conditions like diabetes, heart disease, or Parkinson's work better with their advanced practice nurse. About 420 adults will take part. The goal is to see if this approach improves how pa…

This study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…

This study looks at the bacteria living on the skin and in the gut of 100 adults with and without vitiligo. Researchers want to see if people with active or stable vitiligo have different bacteria compared to healthy volunteers. No treatments or drugs are given—just samples colle…

This study tests a new type of MRI that looks at energy use in the brain to see if it can predict how well multiple sclerosis (MS) patients will respond to a common therapy. Researchers will scan 40 adults with relapsing-remitting MS before and after they start treatment. The goa…

This early-stage study tests a new drug called DWP212525 in 84 healthy adults aged 19 to 55. The main goal is to check safety and how the drug moves through the body. It is the first step in developing a possible treatment for autoimmune diseases.

This study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…

This study looks at how heavy smartphone use impacts neck posture, muscle strength, balance, and tongue pressure in people with rheumatoid arthritis or ankylosing spondylitis. Researchers will compare these patients to healthy individuals to separate the effects of the disease fr…

This study follows 20 adults with multiple sclerosis who are already scheduled for a stem cell transplant. Researchers will measure levels of an immune-suppressing drug called ATLG and track how the immune system rebuilds itself afterward. The goal is to learn more about immune r…

This study looks at why people with rheumatoid arthritis (RA) may have trouble swallowing. Researchers will use a small, flexible camera to examine the throat and voice box in 137 adults with RA. They aim to find factors that predict swallowing difficulty and see if joint problem…

This study looks at how well a non-invasive navigation system helps surgeons place the hip cup during total hip replacement. About 118 people with hip conditions like arthritis or hip dysplasia will take part. The goal is to see if the actual cup position matches the planned posi…

This pilot study tests whether a radioactive tracer called 89Zr-Df-crefmirlimab can help PET scans detect certain immune cells (CD8+ T cells) in the brain and spinal cord of people with multiple sclerosis (MS) or progressive multifocal leukoencephalopathy (PML). About 15 adults w…

This study follows 250 adults with multiple sclerosis (or similar conditions) for years, using yearly MRI scans and other tests to track brain and spinal cord changes. After a participant passes away, researchers examine donated brain and spinal cord tissue to see how the MRI fin…

This study is testing whether a mobile app called Fabla-diabetesMM, which lets people record audio diaries, is easy and helpful for older adults with type 1 or 2 diabetes who also have other health conditions. Thirty participants will use the app and answer questions about their …

This study aims to create better custom insoles for people with rheumatoid arthritis who have foot pain. Researchers will use CT scans and motion analysis to build a digital model of how feet move and apply pressure. The goal is to design insoles that reduce pain and improve comf…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study looks at how social factors and health literacy affect the ability of people with diabetes to manage their own care. Researchers will survey 400 adults with type 1 or type 2 diabetes to understand these connections. The goal is to design better support programs that he…

This study follows up to 5,000 people with autoinflammatory diseases (like NOMID, CANDLE, and juvenile dermatomyositis) and their healthy relatives. Researchers will collect medical history, blood samples, and imaging over 2-5 day visits to learn how these diseases work and find …

This study looks at whether improving sleep and circadian timing can reduce heart disease risk in adolescents with type 1 diabetes who typically sleep less than 7 hours per night. Fifty teens will follow a one-month program that includes a longer sleep schedule, a low dose of mel…

This study looks at whether a genetic risk score can predict which people with newly diagnosed diabetes will eventually need insulin. Researchers will follow about 3,000 patients aged 14 to 50 for up to 3 years, tracking their C-peptide levels (a marker of insulin production) and…

This study is testing whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can better tell apart brain lesions caused by multiple sclerosis (MS) from those due to normal aging or small vessel disease. Researchers will scan 1,000 people aged 50-70 wit…

This observational study looks at how sleep quality influences cognitive flexibility, physical activity, body awareness, and reaction time in people with multiple sclerosis. Researchers will compare those with good and poor sleep using questionnaires, computer tests, and a wearab…

This study is not testing a new drug. Instead, it will observe 800 people with relapsing multiple sclerosis in Germany who are already taking approved injectable or oral medications. Researchers will track how long patients stick with their prescribed treatment over up to four ye…

This study looks at how having both sleep apnea and COPD (called overlap syndrome) affects the heart. Researchers will compare people with one or both conditions and test two breathing treatments—a special mask that helps breathing at night and extra oxygen—to see which may impro…

This study uses a special PET scan to measure brain inflammation in people with fibromyalgia, chronic fatigue syndrome, multiple sclerosis, and healthy volunteers. Researchers want to see if those with pain and fatigue have higher levels of brain inflammation. The study does not …

This study looks for inherited genes that may increase the risk of developing antiphospholipid antibody syndrome (APS), a condition that causes abnormal blood clotting, leading to problems like strokes, heart attacks, and miscarriages. Researchers will recruit 2,800 people with A…

This study from Mayo Clinic looks at how multiple sclerosis (MS) affects the autonomic nervous system, which controls things like blood pressure, skin blood flow, and bladder health. Researchers will compare 13 people with MS to healthy volunteers using simple lab tests. The goal…

This study follows 842 people with multiple sclerosis who are starting a new under-the-skin injection of ocrelizumab. Researchers will ask participants how satisfied they are with the injection after 1, 6, and 12 months. The goal is to understand patient experience, not to test t…

This study looks at 40 adults with psoriasis—some with joint pain (psoriatic arthritis) and some without—to compare immune signals in their blood and skin. Researchers want to understand why some people develop joint problems. Participants give blood and skin samples for lab anal…

This study observes 60 people with stage 2 type 1 diabetes who received teplizumab as part of managed access programs. Researchers will review medical records to describe patient characteristics, monitoring practices, and how long it takes for diabetes to progress. The goal is to…

This study tests a special dye and camera to look at lymph vessels in the hands of people with rheumatoid arthritis. The dye is injected into the skin and glows under a near-infrared camera, allowing researchers to see how lymph fluid moves. The goal is to better understand how t…

This study looks at immune cells in the gut to understand how they might be linked to multiple sclerosis, Parkinson's disease, and REM sleep behavior disorder. Researchers will collect colon tissue samples from 100 adults during colonoscopy. The goal is to map these cells and the…

This study tracks 240 pregnant women with lupus who have taken anifrolumab (Saphnelo) to see if the drug affects pregnancy or baby health. Researchers will monitor for birth defects and other complications. The goal is to gather safety information, not to test a new treatment.

This study looks at how body awareness (knowing where your body is in space), trunk (core) stability, and arm function are related in people with multiple sclerosis (MS). Researchers will measure these abilities in 50 adults with MS and compare them to healthy volunteers. The goa…

This study looks at 600 teens and young adults (ages 14-26) with conditions like juvenile arthritis, fibromyalgia, or past surgeries to understand why some develop long-lasting pain while others don't. Researchers will examine pain sensitivity, immune markers, and social factors …

This study collects blood, spinal fluid, and brain tissue from 400 people with severe seizures (status epilepticus) or epilepsy linked to brain inflammation (dysimmune encephalitis), plus control patients. Researchers aim to find antibodies and markers of nerve cell death that co…